CELZ Creative Medical Technology (CELZ) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001187953
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
9
13F, latest reported quarter
What the filings say about CELZ
Activist stakes (13D), 180 days
1 filing
Largest: 13.7% of the class
Creative Medical Technology insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 4 earlier Form 4 trades (code P or S) here by this insider (3 buys, 1 sale), the last on Feb 18, 2025.
- -28.2% median (-19.0% mean) 90-day return after 3 previous buys.
- The trade is 213.7% of the 351 shares held after it.
- No other insider sold within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Finger Michael H. sold about $4.3K of CELZ on Feb 19, 2025, the largest insider sale at the company since 2021; 9 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Sep 27, 2022.
- -28.2% median (-19.0% mean) 90-day return after 3 previous buys.
- The trade is 68.1% of the 1,101 shares held after it.
- No other insider sold within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Finger Michael H. sold about $3.8K of CELZ on Feb 18, 2025, the largest insider sale at the company since 2021; 9 funds added in the latest 13F quarter.Context
- 16 earlier Form 4 trades (code P or S) here by this insider (16 buys), the last on Jun 27, 2023.
- -25.9% median (+11.1% mean) 90-day return after 7 previous buys.
- The trade is 1.6% of the 12,209 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Warbington Timothy bought about $872 of CELZ on Jun 28, 2023; 9 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 buys), the last on Nov 22, 2022.
- -27.0% median (+10.4% mean) 90-day return after 6 previous buys.
- The trade is 1.7% of the 12,009 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Warbington Timothy bought about $896 of CELZ on Jun 27, 2023; 9 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 buys), the last on Nov 22, 2022.
- -27.0% median (+10.4% mean) 90-day return after 6 previous buys.
- The trade is 2.6% of the 11,509 shares held after it.
- No other insider bought within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Warbington Timothy bought about $1.3K of CELZ on Jun 27, 2023; 9 funds added in the latest 13F quarter.25 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
9 funds bought in last quarter
below 86% of Pharma & Biotech
Revenue
-45.5% year over year
below 78% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
$10.0K repurchased, FY to 2025-12-31
the lowest in Pharma & Biotech
Short interest
2.5% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 63% of Pharma & Biotech
The situation: each line is one rule over one dataset
Timothy Warbington disclosed a 5%+ stake (13.7%) in the last six months.
What changed in the last 30 days
Oct 1Timothy Warbington filed a 13D for 13.7%
Oct 1Creative Acquisition Corp. filed a 13D for 13.2%
Watch CELZ
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-82.8%12M
13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CELZ: institutional holders (13F)
13F holdings, latest reported quarter
135,170 sh
$196.0K
105,549 sh
$153.0K
42,000 sh
$60.9K
26,559 sh
$38.5K
25,799 sh
$37.4K
Congress trades in CELZ
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Timothy Warbington
Activist 13D · 2026-10-01
13.7%
Creative Acquisition Corp.
Activist 13D · 2026-10-01
13.2%
CELZ planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CELZ mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$62.0K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$29.5K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$8.9K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$3.5K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Not applicable
1 active
2
Multi-phase
2 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 9 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CELZ financials
Revenue growth
-45.5%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.0K
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CELZ
| FY Dec 2025 | $6.0K |
| FY Dec 2024 | $11.0K |
| FY Dec 2023 | $9.0K |
| FY Dec 2022 | $88.6K |
| FY Dec 2021 | $87.8K |
| Jun 2026 | $0 |
| Mar 2026 | $0 |
| Dec 2025 | $3.0K |
| Sep 2025 | $0 |
| Jun 2025 | $0 |
| Mar 2025 | $3.0K |
| Dec 2024 | $3.0K |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM CELZ
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM CELZ
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.59x
long-term debt only, 2021-09-30 (57 months older than the period end); equity 2026-06-30
Debt to equity CELZ
| FY Dec 2025 | 0.68x |
| FY Dec 2024 | 0.81x |
| FY Dec 2023 | 0.50x |
| FY Dec 2022 | 0.32x |
| FY Dec 2021 | 0.50x |
| Jun 2026 | 0.59x |
| Mar 2026 | 0.84x |
| Dec 2025 | 0.68x |
| Sep 2025 | 0.92x |
| Jun 2025 | 0.75x |
| Mar 2025 | 0.64x |
| Dec 2024 | 0.81x |
| Sep 2024 | 0.78x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1.15x
TTM operating cash flow over long-term debt only, 2021-09-30 (57 months older than the period end)
Cash flow to debt CELZ
| FY Dec 2025 | -1.14x |
| FY Dec 2024 | -1.03x |
| FY Dec 2023 | -1.56x |
| FY Dec 2022 | -1.52x |
| FY Dec 2021 | -0.43x |
| Jun 2026 | -1.15x |
| Mar 2026 | -1.09x |
| Dec 2025 | -1.14x |
| Sep 2025 | -1.14x |
| Jun 2025 | -1.10x |
| Mar 2025 | -1.17x |
| Dec 2024 | -1.03x |
| Sep 2024 | -1.02x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-78.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CELZ
| FY Dec 2025 | -86.5% |
| FY Dec 2024 | -65.8% |
| FY Dec 2023 | -40.3% |
| FY Dec 2022 | -77.8% |
| FY Dec 2021 | n/a |
| Jun 2026 | -78.0% |
| Mar 2026 | -81.3% |
| Dec 2025 | -86.5% |
| Sep 2025 | -98.1% |
| Jun 2025 | -79.9% |
| Mar 2025 | -70.4% |
| Dec 2024 | -65.8% |
| Sep 2024 | -57.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-73.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CELZ
| FY Dec 2025 | -82.8% |
| FY Dec 2024 | -63.2% |
| FY Dec 2023 | -35.4% |
| FY Dec 2022 | -66.6% |
| FY Dec 2021 | +320.6% |
| Jun 2026 | -73.3% |
| Mar 2026 | -77.9% |
| Dec 2025 | -82.8% |
| Sep 2025 | -93.6% |
| Jun 2025 | -76.4% |
| Mar 2025 | -67.8% |
| Dec 2024 | -63.2% |
| Sep 2024 | -54.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital CELZ
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-80.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CELZ
| FY Dec 2025 | -88.6% |
| FY Dec 2024 | -68.8% |
| FY Dec 2023 | -42.9% |
| FY Dec 2022 | -78.6% |
| FY Dec 2021 | n/a |
| Jun 2026 | -80.5% |
| Mar 2026 | -83.7% |
| Dec 2025 | -88.6% |
| Sep 2025 | -100.1% |
| Jun 2025 | -82.0% |
| Mar 2025 | -72.7% |
| Dec 2024 | -68.8% |
| Sep 2024 | -60.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CELZ
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 4.40x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$5.3M
market value at close 2026-10-26 on 2026-08-07 shares, plus long-term debt only, 2021-09-30 (57 months older than the period end), minus cash 2023-09-30
Enterprise value CELZ
| FY Dec 2025 | $5.7M |
| FY Dec 2024 | $4.7M |
| FY Dec 2023 | $7.0M |
| FY Dec 2022 | $50.5M |
| FY Dec 2021 | $48.6M |
| Jun 2026 | $6.0M |
| Mar 2026 | $8.3M |
| Dec 2025 | $5.7M |
| Sep 2025 | $9.2M |
| Jun 2025 | $7.5M |
| Mar 2025 | $4.4M |
| Dec 2024 | $4.7M |
| Sep 2024 | $4.8M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield CELZ
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CELZ
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $6.0K | $11.0K | $9.0K | $88.6K |
| Gross profit | $3.8K | $6.6K | $5.4K | $60.1K |
| Operating income | -$6.1M | -$5.7M | -$5.6M | -$10.2M |
| Net income | -$6.0M | -$5.5M | -$5.3M | -$10.1M |
| EPS (diluted) | -2.52 | -3.71 | -3.76 | -0.93 |
| Operating cash flow | -$5.9M | -$5.3M | -$8.0M | -$7.8M |
| Cash | n/a | n/a | n/a | $8.3M |
| Buybacks | $10.0K | $175.0K | $271.0K | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
CELZ Stock Sonar score 5/7 axes
Find similar shapesCompareCELZ ranks highest on risk and compliance (84th percentile) and financial health (39th), and lowest on institutional and government (14th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CELZ filings, in plain words
Read the full summary
1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 13.7% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
